- Motus GI ( NASDAQ: MOTS ) said on Wednesday that pre-clinical tests showed enhanced functionality of Pure-Vu EVS that can help overcome common visualization challenges encountered during emergency upper GI bleeding procedures.
- The company said additional pre-clinical and clinical tests of Pure-Vu EVS System are planned in 1H 2023; development program on track to submit marketing application to the U.S. FDA in 2H 2023.
- It is also plans to evaluate potential strategic distribution and licensing partnerships in U.S. and abroad.
For further details see:
Motus GI reports positive pre-clinical data from Pure-Vu EVS trial for use in Upper GI bleeding procedures